- Home
- VCEL vs BLTE Comparison
VCEL vs BLTE Comparison
Compare VCEL & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCEL
- BLTE
- Stock Information
- Founded
- VCEL 1989
- BLTE 2018
- Country
- VCEL United States
- BLTE United States
- Employees
- VCEL N/A
- BLTE N/A
- Industry
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- VCEL Health Care
- BLTE Health Care
- Exchange
- VCEL Nasdaq
- BLTE Nasdaq
- Market Cap
- VCEL 2.1B
- BLTE 2.1B
- IPO Year
- VCEL 1997
- BLTE 2022
- Fundamental
- Price
- VCEL $40.12
- BLTE $62.24
- Analyst Decision
- VCEL Strong Buy
- BLTE Strong Buy
- Analyst Count
- VCEL 8
- BLTE 4
- Target Price
- VCEL $62.00
- BLTE $96.67
- AVG Volume (30 Days)
- VCEL 558.9K
- BLTE 71.7K
- Earning Date
- VCEL 07-31-2025
- BLTE 08-08-2025
- Dividend Yield
- VCEL N/A
- BLTE N/A
- EPS Growth
- VCEL 521.85
- BLTE N/A
- EPS
- VCEL 0.05
- BLTE N/A
- Revenue
- VCEL $238,541,000.00
- BLTE N/A
- Revenue This Year
- VCEL $23.03
- BLTE N/A
- Revenue Next Year
- VCEL $24.52
- BLTE N/A
- P/E Ratio
- VCEL $772.69
- BLTE N/A
- Revenue Growth
- VCEL 14.80
- BLTE N/A
- 52 Week Low
- VCEL $34.87
- BLTE $43.70
- 52 Week High
- VCEL $63.00
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- VCEL 51.37
- BLTE 53.07
- Support Level
- VCEL $34.87
- BLTE $59.12
- Resistance Level
- VCEL $41.00
- BLTE $62.64
- Average True Range (ATR)
- VCEL 1.77
- BLTE 2.29
- MACD
- VCEL 0.21
- BLTE 0.11
- Stochastic Oscillator
- VCEL 67.83
- BLTE 53.14
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.